Solide tumoren, fase I, MET, MET kinase inhibitor
T4N0 / stadium III resectabel coloncarcinoom, MSI-H; perioperatief dostarlimab versus SOC
Adenocarcinoom slokdarm maag, fase II, HER2-, F-doublets (F-Nal-IRI, CapCar and CapOx)
Rectumcarcinoom, fase III, clear resection margin (R0 resection)
dMMR oesofagogastrisch carcinoom, fase II, HER2-negatief, MSI-positief
CROSS neoadjuvante chemoradiotherapie, fase II, actieve surveillance, nivolumab
Oesofaguscarcinoom, fase III, operabel HER2-positief
Solide tumoren, ‘actionable’ moleculaire target
Solide tumoren, EMA geregistreerde middelen
